With An Additional Active Ingredient (excludes Reaction Product Or Complex) Patents (Class 514/154)
-
Patent number: 6100248Abstract: The invention is a method of inhibiting cancer growth, by inhibiting cellular proliferation, invasiveness, or metastasis, or by inducing cytotoxicity against cancer in mammals. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.Type: GrantFiled: January 15, 1998Date of Patent: August 8, 2000Inventors: Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block
-
Patent number: 5998390Abstract: Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.Type: GrantFiled: September 28, 1998Date of Patent: December 7, 1999Assignee: The Research Foundation of State University of New YorkInventors: Nungavarm S. Ramamurthy, Lorne M. Golub, Timo A. Sorsa, Olli P. Teronen, Tuula A. Salo
-
Patent number: 5989832Abstract: Methods are provided for screening for inhibitors of microbial efflux pumps including those which export antibiotics. The screening methods are based on the increase in the intracellular concentration of a compound, such as an antibiotic, when the bacterial cells are contacted with an efflux pump inhibitor. In addition, this invention provides pharmaceutical compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions.Type: GrantFiled: April 21, 1995Date of Patent: November 23, 1999Assignee: Microcide Pharmaceuticals, Inc.Inventors: Joaquim Trias, Suzanne Chamberland, Scott J. Hecker, Ving J. Lee
-
Patent number: 5883074Abstract: Methods for screening for compounds which potentiate the activity of antibacterial agents against bacteria resistant to the antibacterial agent alone, pharmaceutical compositions including such potentiators, and methods of treating bacterial infections using a combination of a potentiator and a potentiated antibacterial agent, which are useful for overcoming the resistance of a bacterial strain for an antibacterial agent.Type: GrantFiled: February 8, 1995Date of Patent: March 16, 1999Assignee: Microcide Pharmaceuticals, Inc.Inventors: Amy Boggs, Joaquim Trias, Scott Hecker
-
Patent number: 5856315Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: May 26, 1998Date of Patent: January 5, 1999Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5843925Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: December 1, 1998Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5837696Abstract: The invention is a method of inhibiting cancer growth, including cellular proliferation, invasiveness, or metastasis in mammals. The method employs 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.Type: GrantFiled: January 15, 1997Date of Patent: November 17, 1998Assignees: The Research Foundation of State University of New York, University of MiamiInventors: Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block
-
Patent number: 5827543Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa.Type: GrantFiled: December 7, 1995Date of Patent: October 27, 1998Assignee: The Procter & Gamble CompanyInventor: Jamesina Anne Fitzgerald
-
Patent number: 5811412Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: GrantFiled: September 30, 1996Date of Patent: September 22, 1998Assignee: The Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 5744168Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria.Type: GrantFiled: December 7, 1995Date of Patent: April 28, 1998Assignee: The Procter & Gamble CompanyInventor: Jamesina Anne Fitzgerald
-
Patent number: 5674858Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.Type: GrantFiled: June 5, 1995Date of Patent: October 7, 1997Assignee: Glaxo Group LimitedInventor: Andrew Alexander McColm
-
Patent number: 5674539Abstract: A topical medication for the treatment of skin pathology including acne is comprised of tetracycline, minocycline, clindamycin, erythromycin, or doxicycline and selenium sulfide or sulfur in a pharmaceutically acceptable carrier. The lotion, cream or ointment is applied to the lesions, left in place briefly and washed off. This is repeated twice daily. The lesions generally clear up within a week. Because the treatment is local, the serious side effects of systemic administration of drugs is avoided.Type: GrantFiled: May 18, 1995Date of Patent: October 7, 1997Inventor: Robert E. Tomas
-
Patent number: 5618564Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.Type: GrantFiled: July 27, 1995Date of Patent: April 8, 1997Assignees: Ken Kimura, Kaken Pharmaceutical Co., Ltd.Inventors: Ken Kimura, Yushi Taniguchi, Kiichi Satoh, Kouji Saifuku, Ken Kihira, Kenichi Ido, Yukio Yoshida, Takuya Takimoto
-
Patent number: 5604208Abstract: An antibiotic formulation comprising gentamicin, and optionally tetracycline or oxytetracycline, for use in plants.Type: GrantFiled: January 30, 1995Date of Patent: February 18, 1997Assignee: Quimica Agronomica de Mexica, S.de.R.L.MI.Inventor: Miguel E. Alvarado-Licon
-
Patent number: 5589470Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, C5 ester novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: GrantFiled: June 14, 1994Date of Patent: December 31, 1996Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 5574026Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-halogen-9-[hydrogen or [(substituted glycyl)amido]]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: November 12, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
-
Patent number: 5567693Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C.sub.1 -C.sub.4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: October 22, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
-
Patent number: 5563130Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R.sub.2 and R.sub.3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: October 8, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5476669Abstract: A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.Type: GrantFiled: August 31, 1992Date of Patent: December 19, 1995Assignees: Examed Australia Pty. Ltd., Ostapat Pty. Limited, Gastro Services Pty. Limited, Capability Services Pty. LimitedInventor: Thomas J. Borody
-
Patent number: 5312813Abstract: A method of killing microorganisms which form a biofilm on a tissue or implant surfaces in a patient, and which are refractory to a biocide at a dose which is effective to kill the microorganism in planktonic form. The effect of the biocide is potentiated, to an effective killing level, by applying an electric field across the surface containing the biofilm.Type: GrantFiled: July 22, 1992Date of Patent: May 17, 1994Assignee: University Technologies InternationalInventors: John W. F. Costerton, Antoine E. Khoury, Frank Johnson
-
Patent number: 5258372Abstract: Methods and products for overcoming bacterial resistance to tetracycline-type antibiotics by inhibiting the plasmid-mediated active efflux system for tetracycline in the resistant bacterial cell by administering with tetracycline efflux system blocking agents of doxycycline or sancycline, thereby increasing the sensitivity of the resistant cell to tetracycline type antibiotics.Type: GrantFiled: March 20, 1991Date of Patent: November 2, 1993Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 5256684Abstract: Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.Type: GrantFiled: July 26, 1991Date of Patent: October 26, 1993Assignee: The Procter & Gamble CompanyInventor: Barry J. Marshall
-
Patent number: 5196205Abstract: A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.Type: GrantFiled: June 12, 1990Date of Patent: March 23, 1993Inventor: Thomas J. Borody
-
Patent number: 5064821Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs 13-(substituted mercapto) derivatives of tetracycline in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously or concurrently. The concomittantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state. The combination also effects a synergistic bacteriocidal activity against susceptible and resistant cells.Type: GrantFiled: February 26, 1990Date of Patent: November 12, 1991Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 5021407Abstract: Methods and products for overcoming bacterial resistance to tetracycline-type antibiotics by inhibiting the plasmid-mediated active efflux system for tetracycline in the resistant bacterial cell by administering with tetracycline efflux system blocking agents, thereby increasing the sensitivity of the resistant cell to tetracycline-type antibiotics.Type: GrantFiled: April 11, 1986Date of Patent: June 4, 1991Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 4997823Abstract: Infection associated with parenteral injections of parenterally suitable compounds, especially of F.sub.2.alpha. prostaglandins, is prevented by novel compositions comprising such compounds, a locally effective amount of an antibiotic, and a pharmaceutically acceptable carrier.Type: GrantFiled: July 20, 1987Date of Patent: March 5, 1991Assignee: Syntex (U.S.A.) Inc.Inventor: Richard C. Herschler
-
Patent number: 4973595Abstract: The hatchability of fertile turkey eggs is increased by injection of the eggs with an effective amount of exogenous pyridoxine. The eggs are preferably injected between the outer and inner membranes following up to 25 days of incubation. Hatchability increases up to 5% have been observed.Type: GrantFiled: June 8, 1989Date of Patent: November 27, 1990Assignee: The United States of America as represented by the Secretary of AgricultureInventor: Edward J. Robel
-
Patent number: 4911924Abstract: Microorganisms carrying tetracycline-resistant determinants are hypersensitized to Sm- and 2-DOS- aminoglycoside antibiotics by exposure to subinhibitory amounts of tetracycline inducer.Type: GrantFiled: April 17, 1987Date of Patent: March 27, 1990Assignee: University of New MexicoInventors: Jeffrey K. Griffith, William L. Anderson
-
Patent number: 4904647Abstract: The invention relates to a synergistic, antimicrobial pharmaceutical composition containing 0.01 to 50% by weight of a quinolinecarboxylic acid derivative or a naphthyridinecarboxylic acid derivative of the formula (I), ##STR1## wherein X is carbon or nitrogen;R.sup.1 is hydrogen or fluorine;R.sup.2 is methyl, piperazino or methylpiperazino group; orR.sup.1 and R.sup.2 together are a methylenedioxy group; and 0.01 to 95% by weight of a tetracycline derivative of the formula (II), ##STR2## wherein R.sup.3 and R.sup.4 are hydrogen; orR.sup.3 and R.sup.4 together represent an additional chemical bond,in 20:1 to 1:50 ratio of the compound of the formula (I) to the compound of the formula (II), optionally in an admixture with an amount required to 100% by weight of an inert, solid or liquid carrier such as magnesium carbonate, magnesium stearate, starch, talc, cyclodextrine or water and other additives such as filling, disintegrating, sliding and emulsifying agents.Type: GrantFiled: July 20, 1988Date of Patent: February 27, 1990Assignee: Chinoin Gyogyszer-es Vegyeszeti Termekek Gyara RtInventors: Gabor Kulcsar, Judit Frank, Peter Sarkozy, Katalin Kaloy
-
Patent number: 4879274Abstract: Novel external medications comprise, as essential components, the following three components (A) to (C):(A) an .alpha.-monoglyceryl ether represented by the following formula (I): ##STR1## wherein R means an alkyl or alkenyl group having 10 - 24 carbon atoms; (B) a physiologically active material; and(C) an oily material.The external medications have extremely high skin occlusive properties and significantly-improved absorptivity of phosiologically active materials. Therefore, a smaller amount of the medications compared with the conventional ones can give sufficient pharmacological effects and thus side effects can be reduced. The external medications may contain physiologically active materials such as drugs, growth hormones and the like, which are expected to show pharmacological effects upon their percutaneous absorption.Type: GrantFiled: September 12, 1986Date of Patent: November 7, 1989Assignee: Kao CorporationInventors: Tetsuro Kamiya, Shuichi Tsuchiya, Kenji Hara
-
Patent number: 4806529Abstract: Methods and products for overcoming bacterial resistance to tetracycline-type antibiotics by inhibiting the plasmid-mediated active efflux system for tetracycline in the resistant bacterial cell by administering with tetracycline efflux system blocking agents, thereby increasing the sensitivity of the resistant cell to tetracycline type antibiotics.Type: GrantFiled: November 18, 1982Date of Patent: February 21, 1989Assignee: Trustees of Tufts College, Tufts UniversityInventor: Stuart B. Levy
-
Patent number: 4781920Abstract: The invention provides physically stable anthelmintic paste compositions containing resinates of d1-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole and other anthelmintic compounds in combination with a wide variety of therapeutic agents such as antibiotics, vitamins, vaccines, or mineral supplements.Type: GrantFiled: September 3, 1985Date of Patent: November 1, 1988Assignee: American Cyanamid CompanyInventor: James M. Quinlan
-
Patent number: 4650668Abstract: A treatment for temporary relief of pain wherein a single dose comprises the following: 4 grams calcium gluconate by injection, 1 gram Vitamin C (calcium ascorbate), 100 mg magnesium hydroxide, 50 mg Vitamin B.sub.6 (pyridoxine hydrochloride), 1 gram pantothenic acid, effervescent solution.Type: GrantFiled: December 21, 1984Date of Patent: March 17, 1987Inventors: Larry Barron, Susan C. Barron
-
Patent number: 4607101Abstract: An improved method of treating acne vulgaris comprising administering a therapeutically effective amount of carbamide peroxide alone or in combination with one or more of a topical antibiotic, nicotinic acid or nicotinamide and compositions useful in said method.Type: GrantFiled: March 27, 1984Date of Patent: August 19, 1986Assignee: Jaye-Boern Laboratories, Inc.Inventor: Joel E. Bernstein
-
Patent number: 4560553Abstract: Eucalyptol is used to enhance skin permeation of bio-affecting agents.Type: GrantFiled: November 21, 1983Date of Patent: December 24, 1985Assignee: Merck & Co., Inc.Inventor: Jacob A. Zupan
-
Patent number: 4505896Abstract: An improved method of treating acne vulgaris comprising administering a therapeutically effective amount of nicotinic acid or nicotinamide and compositions useful in said method.Type: GrantFiled: November 24, 1980Date of Patent: March 19, 1985Assignee: Elorac, Ltd.Inventor: Joel E. Bernstein